The Metabolic Syndrome and Cardiovascular Risk

Jewish General Hospital/McGill University, Montreal, Quebec, Canada.
Journal of the American College of Cardiology (Impact Factor: 15.34). 09/2010; 56(14):1113-32. DOI: 10.1016/j.jacc.2010.05.034
Source: PubMed

ABSTRACT We sought to conduct a systematic review and meta-analysis of the cardiovascular risk associated with the metabolic syndrome as defined by the 2001 National Cholesterol Education Program (NCEP) and 2004 revised National Cholesterol Education Program (rNCEP) definitions.
Numerous studies have investigated the cardiovascular risk associated with the NCEP and rNCEP definitions of the metabolic syndrome. There is debate regarding the prognostic significance of the metabolic syndrome for cardiovascular outcomes.
We searched the Cochrane Library, EMBASE, and Medline databases through June 2009 for prospective observational studies investigating the cardiovascular effects of the metabolic syndrome. Two reviewers extracted data, which were aggregated using random-effects models.
We identified 87 studies, which included 951,083 patients (NCEP: 63 studies, 497,651 patients; rNCEP: 33 studies, 453,432 patients). There was little variation between the cardiovascular risk associated with NCEP and rNCEP definitions. When both definitions were pooled, the metabolic syndrome was associated with an increased risk of cardiovascular disease (CVD) (relative risk [RR]: 2.35; 95% confidence interval [CI]: 2.02 to 2.73), CVD mortality (RR: 2.40; 95% CI: 1.87 to 3.08), all-cause mortality (RR: 1.58; 95% CI: 1.39 to 1.78), myocardial infarction (RR: 1.99; 95% CI: 1.61 to 2.46), and stroke (RR: 2.27; 95% CI: 1.80 to 2.85). Patients with the metabolic syndrome, but without diabetes, maintained a high cardiovascular risk.
The metabolic syndrome is associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality. Studies are needed to investigate whether or not the prognostic significance of the metabolic syndrome exceeds the risk associated with the sum of its individual components. Furthermore, studies are needed to elucidate the mechanisms by which the metabolic syndrome increases cardiovascular risk.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with metabolic syndrome are at increased risk for cardiovascular disease. Combination lipid-lowering therapy is often needed in patients with metabolic syndrome and mixed dyslipidemia. The aim of this study was to compare the effect of statin combined with a new hypolipidemic agent, coenzyme A (CoA) with moderate-dose statin monotherapy in subjects with metabolic syndrome and mixed dyslipidemia by evaluating data from a subgroup of patients with metabolic syndrome and mixed dyslipidemia from a previously conducted randomized study. In the present post hoc analysis, 212 patients were included, receiving statin monotherapy (n = 94) or statin combined with CoA 400 U/day (n = 118) for 8 weeks. The lipoprotein profile was determined at baseline and week 8 visits. Attainment of low-density lipoprotein-cholesterol (LDL-C) < 100 mg/dL, non-high-density lipoprotein-cholesterol (HDL-C) < 130 mg/dL, and the combined goal of these two parameters was also evaluated. The mean percent change was more prominent with CoA plus statin compared with placebo plus statin in triglyceride (TG) (-32.5% vs. -8.7%, respectively; P = 0.0002), total cholesterol (-9.6% vs. -3.6%, P = 0.013), LDL-C (-7.5% vs. 2.1%, P = 0.033), and non-HDL-C (-14.3% vs. -6.4%, P = 0.011). Treatment with CoA plus statin resulted in larger percentages of participants attaining lipid goals for LDL-C (70.3% vs. 56.4%, P = 0.044), non-HDL-C (60.2% vs. 45.7%, P = 0.039), and the combined goal of LDL-C and non-HDL-C (57.6% vs. 42.6%, P = 0.038) than statin monotherapy. These results demonstrate that CoA plus statin therapy was more effective in improving lipoprotein parameters than statin alone in patients with metabolic syndrome and mixed hyperlipidemia.
    Journal of Clinical Medicine Research 06/2015; 7(6):446-52. DOI:10.14740/jocmr2124w
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Blood ferritin level has been associated with a wide range of chronic diseases, including diabetes and cardiovascular disease. However, whether elevated ferritin levels affect the risk of developing metabolic syndrome remains unknown. Objective: The aim was to examine the putative relationship between serum ferritin level and metabolic syndrome in the general adult population by performing a dose-response meta-analysis of 90,000 individuals. Design: Dose-response meta-analysis of observational studies. Data Source: To identify relevant studies, we performed a comprehensive search of the databases PubMed and Web of Science for studies published through May 2014. Study Selection: We selected observational studies that reported relative risk (RR) with 95% confidence interval (CI) for metabolic syndrome based on circulating ferritin levels. In total, 88,489 participants and 14,429 metabolic syndrome cases were analyzed from 11 studies. Results: The pooled RR of metabolic syndrome in the highest versus lowest ferritin level quartiles were significantly elevated in both the retrospective studies (RR: 1.90; 95% CI: 1.56-2.31; I2 = 79.4%) and prospective cohort studies (RR: 1.56; 95% CI: 1.36-1.78; I2 = 0%). The dose-response meta-analysis revealed a generally positive association with an incremental change of 25 ng/m in blood ferritin concentration (RR: 1.07; 95% CI: 1.05-1.09). Conclusions: Our results suggest that ferritin levels, which reflect the body’s iron stores, are significantly and positively associated with the risk factors for metabolic syndrome (with the exception of high blood pressure). Moreover, two prospective studies indicate that blood ferritin levels may have a causal role in the development of metabolic syndrome. More prospective studies are needed to validate the finding.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with increased cardiovascular (CV) morbidity and mortality. This increased CV burden is the result of an enhanced prevalence of traditional CV risk factors, the effects of treatments given for RA but also systemic inflammation. In this setting, the control of inflammation by the current therapeutic approach may improve the overall CV prognosis of RA.Areas covered: This paper analyses the impact of TNFα inhibitors on the different CV risk factors with a special emphasis on lipid profile and body composition. The lipid profile under TNFα inhibitors changes, an increase in total and high density lipoprotein (HDL) cholesterol is observed but the atherogenic index and low density lioprotein cholesterol are unaffected. In parallel, TNFα inhibitors induce an accumulation of fat in the abdominal/visceral region. Analysis of cohort and registry studies indicates that CV events are reduced under this treatment.Expert opinion: Overall, the favourable CV effect under TNFα inhibitors does not seem to be explained by the changes in traditional CV risk factors, but rather by the improvement in systemic inflammation. Alternatively, the changes in body composition raise the question of their effect on long-term CV safety.
    Expert Opinion on Drug Safety 01/2015; 14(4). DOI:10.1517/14740338.2015.1007041 · 2.74 Impact Factor